

Alliance Vaccinex

Lonza Biologics and Vaccinex Announce Strategic Alliance

07/11/2003

Lonza Biologics and Vaccinex Announce Strategic Alliance

Lonza Biologics (Lonza) and Vaccinex, Inc. today announced a strategic alliance that offers their respective clients a broad range of antibody discovery and manufacturing services.

Lonza will provide Vaccinex, its clients and co-development partners with access to its proprietary Glutamine Synthetase Gene Expression system, which offers important advantages including high yielding cell lines, ease of use and regulatory familiarity. In addition, for a period of five years, Lonza will provide dedicated access to its cGMP manufacturing facilities for the clinical production of recombinant proteins and antibody products. Vaccinex will offer antibody discovery services to Lonza's clients seeking to identify novel therapeutic antibodies. Vaccinex's library-based antibody discovery technology is unique in that it can directly express complete, fully human antibodies in mammalian cells. Both parties will assist each other in the marketing of their respective antibody service offerings to clients.

"By coordinating the discovery and clinical manufacturing processes, we are able to offer our clients a more efficient and predictable pathway for product development. In addition, Vaccinex, our clients and co-development partners will benefit from obtaining access to Lonza's world-class antibody manufacturing facilities and expertise," said Dr. Maurice Zauderer, President and CEO of Vaccinex.

"Integrating Vaccinex's innovative library-based antibody discovery technology with the GS Gene Expression System will offer true value to customers by producing substantial quantities of high quality, fully functional human monoclonal antibodies that would have been difficult to identify with other systems. Moreover this relationship will facilitate a rapid and smooth transition from product discovery to clinical manufacture," said Markus Gemuend, CEO of Lonza Group.

About Lonza

Lonza is a Life Sciences driven company headquartered in Switzerland, with sales of CHF 2.54 billion in 2002 and operating 18 production and R&D facilities in 8 countries. It employs 6 200 people worldwide and is the leading custom manufacturer of active chemical ingredients, intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. It also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds. For more information on Lonza please visit the company's website at www.lonza.com.

About Vaccinex, Inc.

Vaccinex is a privately held biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Therapeutic antibodies have become one of the largest and fastest growing sectors of biotechnology, currently representing approximately 20% of all drugs in the biotechnology pipeline. Vaccinex's antibody discovery platform is one of the only library-based antibody technologies that can directly express complete, fully human antibodies in mammalian cells. The company is commercializing this technology by offering antibody discovery services to clients worldwide and is developing its own proprietary therapeutic products, initially focused on cancer. The firm is headquartered in Rochester, New York and currently has over 30 employees. For additional information, please visit the company's website at www.vaccinex.com.

For further information please contact:

Lonza Group Ltd
Walter Eschenmoser
Communications & Investor Relations
Tel +41 61 316 8363
Fax +41 61 316 8220
walter.eschenmoser@lonza.com

Vaccinex, Inc.
Stan Holland
1895 Mt. Hope Avenue
Rochester, NY 14620
Tel +1 585.271.2700
Fax +1 585.271.2766


[Search](#) | [Contact us](#) | [Careers @ Lonza](#) | [Sitemap](#) | [Quick Search](#) [Go](#)

Please read our
before proceeding
Lonza Group Ltd, S

[Home](#) > [Company](#) > [Media Center](#) > [News Archive](#) > 2003

News 2003

[send](#) [pr](#)

Products & Services

[Custom Manufacturing](#)
[Products & Applications](#)
[Technology Platforms](#)

Company

[About us](#)

→ [Media Center](#)

[News Releases](#)

→ [News Archive](#)

[2004](#)

→ [2003](#)

[2002](#)

[2001](#)

[2000](#)

[1999](#)

[1998](#)

[1997](#)

[Reports, Results](#)

[Presentations](#)

[Photo Gallery](#)

[Logos](#)

[Advertisements](#)

[Calendar of Events](#)

[Trade Fairs & Conferences](#)

[Order Publications](#)

[Publications of Lonza employees](#)

[Investor Relations](#)

[Working at Lonza](#)

[Worldwide](#)

[12/16/2003](#) [Genentech and Lonza announce Manufacturing Agreement](#)

[11/07/2003](#) [Publication regarding changes in voting rights according to Art. 21 SESTA](#)

[07/23/2003](#) [Organizational changes MC](#)

[07/23/2003](#) [Lonza - Half-Year Report 2003](#)

[07/23/2003](#) [Webcast Analyst Conference of Lonzas 2003 Half Year Results](#)

[07/14/2003](#) [Microbial manufacturing agreement](#)

[07/11/2003](#) [Alliance Vaccinex](#)

[06/16/2003](#) [Announcement Half Year 2003 Results](#)

[06/12/2003](#) [Price Increase](#)

[05/23/2003](#) [Publication regarding changes in voting rights according to Art. 21 SESTA](#)

[05/19/2003](#) [Up to 90 % of Lonza Biologics Capacity Expansion in Portsmouth, NH, now under contract](#)

[05/19/2003](#) [Lonza revises 2003 outlook](#)

[05/15/2003](#) [Publication regarding changes in voting rights according to Art. 21 SESTA](#)

[03/27/2003](#) [Microbial fermentation](#)

[03/26/2003](#) [Ordinary Shareholders' Meeting of Lonza Group Ltd](#)

[03/13/2003](#) [Price Increase](#)

[03/11/2003](#) [Announcement Annual Report 2002](#)

[03/01/2003](#) [Annual Report 2001](#)

[02/27/2003](#) [Multi-year strategic service level](#)

[02/25/2003](#) [Proposal Board of Directors](#)

[02/25/2003](#) [Oligonucleotide business](#)

[01/23/2003](#) [2002 Results Webcast Conference Call on Demand](#)

[01/22/2003](#) [Year 2002 Results Analyst Conference](#)

[01/22/2003](#) [Results 2002](#)

01/08/2003 Management change

01/06/2003 Agreement for commercial manufacturing